{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'c.', 'severely impaired respiration as defined as 02 saturation that is < 90% at rest on room', 'air,', 'd. uncontrolled diabetes as defined by fasting serum glucose > 1,5 times the upper limit of', 'normal,', 'e. ejection fraction less than 40% (measured at echocardiography),', 'f. significant liver disease such as cirrhosis, active hepatitis or chronic persistent hepatitis,', 'g. active (acute or chronic) infections requiring antimicrobial intervention.', '7. Concomitant treatment with:', 'a.', 'chronic, systemic corticosteroids or another immunosuppressive agent; topical or', 'inhaled corticosteroids are allowed,', 'b. strong CYP3A4 inducers/inhibitors: carbamezepine, phenytoin, rifabutin, rifampin,', \"nafcillin, phenobarbital, St John's wort, itraconazole, ketoconazole, erythromycinum,\", 'clarithromycinum, nefazodone.', '8. Known allergy/sensitivity to sunitinib and/or propranolol.', '9. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.', '10. Immunization with attenuated live vaccines within 30 days of study entry.', '11. Human immunodeficiency virus (HIV) sero-positivity at the study entry or in the past.', '12. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the', 'absorption of sunitinib and/or propranolol (e.g., ulcerative disease, uncontrolled nausea,', 'vomiting, diarrhea, malabsorption syndrome or small bowel resection).', '13. Presence of active, bleeding diathesis.', '14. Major surgery (defined as requiring general anesthesia) and/or significant traumatic injury', '(requiring > 28 days to heal) within 28 days of the study entry; presence of side effects due to', 'any surgery or probable requirement of major surgery during the course of the study.', '15. Present contraindications to propranolol, that include: bronchial asthma, prolonged fasting,', 'acidosis, hypotension (systolic blood pressure less than 90 mmHg, diastolic blood pressure less', 'than 60 mmHg), severe peripheral arterial circulatory disturbance, cardiogenic shock,', \"bradycardia, Prinzmetal's angina, uncontrolled heart failure, second or third degree heart block,\", 'untreated phaeochromocytoma, sick sinus syndrome.', '16. Inability or unwillingness of subject or legal guardian/representative to give written informed', 'consent.', 'Page 26 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', '4.5 Discontinuations', '4.5.1 Discontinuation of Patients', 'Patients will be discontinued from the study in the following circumstances:', '1.', 'Withdrawal of informed consent.', '2.', \"Evidence of progressive disease (PD) including patient's death.\", '3. Recurrent or unacceptable toxicity grade 3 according to The Common Terminology Criteria for', 'Adverse Events (CTCAE), version 4.0.', '4.', 'Karnofsky performance status < 70 observed in three assessment points (visits) in a row.', '5.', 'Development of exclusion criteria or other safety reasons.', '6. Use of illicit drugs or other substances that may, in the opinion of the investigator, have a', 'reasonable chance of contributing to toxicity or otherwise skewing results.', '7.', 'Discontinuation of sunitinib and/or propranolol for more than 14 days (excluding the 2-week', 'rest period for each cycle of sunitinib).', '8.', 'Protocol non-compliance.', 'In all cases, the reason for withdrawal must be recorded in the Case Report Form (CRF) and in the', \"subject's medical records. All patients who discontinue because of adverse events or clinical\", 'laboratory abnormalities should be followed up until they recover or stabilize, and the subsequent', 'outcome recorded.', '4.5.2 Replacement of Patients', 'Patients who discontinue due to toxicity related to one or both study drugs will not be replaced.', 'Patients who discontinue during the first two weeks due to reasons other than toxicity will be', 'replaced.', '4.5.3 Discontinuation of the Study', 'The study will be discontinued if the Investigators judge it necessary for medical, safety, regulatory,', 'or other reasons consistent with applicable laws, regulations, and GCP.', '5. Study Interventions', '5.1 Investigational Products', '5.1.1 Sunitinib (SUTENT\u00ae by Pfizer Inc.)', 'Marketing Authorisation Holder:', 'Pfizer Limited', 'Ramsgate Road', 'Page 27 of 60']\n\n###\n\n", "completion": "END"}